Efficacy and Safety of Extended-Release Oxybutynin in Combination With Tamsulosin for Treatment of Lower Urinary Tract Symptoms in Men: Randomized, Double-Blind, Placebo-Controlled Study

MacDiarmid, Scott A.; Peters, Kenneth M.; Chen, Andrew; Armstrong, Robert B.; Orman, Camille; Aquilina, Joseph W.; Nitti, Victor W.
September 2008
Mayo Clinic Proceedings;Sep2008, Vol. 83 Issue 9, p1002
Academic Journal
OBJECTIVE: To evaluate the efficacy and tolerability of extended-release oxybutynin in combination with the α1-blocker tamsulosin in reducing lower urinary tract symptoms in men. PATIENTS AND METHODS: In this multicenter, double-blind trial performed between March 29, 2004, and June 22, 2005,420 men aged 45 years or older with a total International Prostate Symptom Score (IPSS) of 13 or more and IPSS for storage of 8 or more were randomized to receive tamsulosin (0.4 mg/d) with either extended-release oxybutynin (10 mg/d) or placebo for 12 weeks. Eligibility requirements included a maximum flow rate of 8 mL/s or more with voided volume of 125 mL or more and a postvoid residual volume of 150 mL or less on 2 occasions. Postvoid residual volume and peak flow rates at weeks 4, 8, and 12 were measured. The primary end point was change from baseline in total IPSS after 12 weeks of treatment. Secondary outcomes Included change in IPSSs for storage and quality of life. RESULTS: Tamsulosin combined with extended-release oxybutynin resulted in significantly greater improvement in total IPSS compared with tamsulosin and placebo after 8 (P=.03) and 12 (P=.006) weeks of treatment, and improved IPSS for storage and quality of life at all assessment points (P<.01). The incidence of postvoid residual volume higher than 300 mL was 2.9% (6/209) in patients receiving combination therapy compared with 0.5% (1/209) in patients receiving tamsulosin alone (P=.12). Occurrence of peak flow rates below 5 mL/s was 3.8% (8/209) for combination therapy and 5.7% (12/209) for tamsulosin alone (P=.49). CONCLUSION: In men with substantial storage symptoms, combination therapy with tamsulosin and extended-release oxybutynin demonstrated greater efficacy than and comparable safety and tolerability to tamsulosin monotherapy.


Related Articles

  • Evaluation of greenlight photoselective vaporization of the prostate for the treatment of high-risk patients with benign prostatic hyperplasia. Wei-Jun Fu; Bao-Fa Hong; Xiao-Xiong Wang; Yong Yang; Wei Cai; Jiang-Ping Gao; Yao-Fu Chen; Cui-E Zhang // Asian Journal of Andrology;May2006, Vol. 8 Issue 3, p367 

    Aim: To explore the feasibility and safety of greenlight photoselective vaporization of the prostate (PVP) on high-risk patients presenting with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH) and to evaluate their clinical and voiding outcome. Methods: A total of...

  • A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH. Wu, Y J; Dong, Q; Liu, L R; Wei, Q // Prostate Cancer & Prostatic Diseases;Mar2013, Vol. 16 Issue 1, p79 

    Backgroud:Recently several clinical trials have focused on the efficacy and safety of silodosin, a new, highly selective α1A-blocker. We tried to verify silodosin's superiority to placebo and non-inferiority to tamsulosin in treating patients with lower urinary tract symptoms (LUTS)...

  • Antibiotic and anti-inflammatory use and the risk of prostate cancer. Daniels, Nicholas A.; Yea-Hung Chen; Stephen Bent // BMC Research Notes;2009, Vol. 2, p1 

    Background: Prostate inflammation or infection may increase the risk of prostate cancer. Antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat prostatitis and urinary tract infections (UTIs). The objective of our study was to assess whether their use decreases the risk...

  • A quick, easy way to assess prostate mass.  // Pulse;8/24/2011, Vol. 71 Issue 27, p7 

    The article offers information on a new Case-based learning module on lower urinary tract symptoms in men (LUTS) which offers a quick and easy way o evaluate prostate mass during a digitl rectal examination in Great Britain.

  • Increasing dosage of saw palmetto does not appear to reduce urinary symptoms from enlarged prostate.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p179 

    The article presents a study published in the September 28, 2012 issue of "Journal of the American Medical Association" (JAMA) which reveals that increasing dosage of saw palmetto does not appear to reduce urinary symptoms from enlarged prostate.

  • Immunotherapy shows survival advantage in advanced PCa. Goodman, Alice // Urology Times;1/1/2006, Vol. 34 Issue 1, p6 

    The article reports that immunotherapy agent offers a survival benefit in men with asymptomatic metastatic androgen-independent prostate cancer. In the second trial, D9902A, no statistically significant improvement in time to progression or overall survival was reported, but median survival was...

  • Prostate Cancer Trial Ends Early and With Positive Results. Hogle, William P. // Clinical Journal of Oncology Nursing;Feb2004, Vol. 8 Issue 1, p23 

    Reports on the results of the Prostate Cancer Prevention Trial in the U.S. Comparison on cancer risk of men taking Proscar and placebo; Sexual side effects of the treatment trial; Information on Proscar manufactured by Merck & Co. Inc.

  • Tamsulosin: A Review of its Pharmacology and Therapeutic Efficacy in the Management of Lower Urinary Tract Symptoms. Dunn, C.J.; Matheson, A.; Faulds, D.M. // Drugs & Aging;2002, Vol. 19 Issue 2, p135 

    Tamsulosin is a subtype-selective α- and α-adrenoceptor antagonist. α-Receptors predominate in the prostate gland, prostatic capsule, prostatic urethra and bladder, and the relaxation of prostate and bladder smooth muscles is associated with improved maximal urine flow (Q) and...

  • Current Affairs.  // Urologic Nursing;Feb2001, Vol. 21 Issue 1, p51 

    Reports developments on urology as of February 2001. Details on the emotional impact of prostate cancer to the wives; Causes of urinary tract infection; Detection of prostate cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics